2,881 Shares in Astera Labs, Inc. $ALAB Acquired by Callan Family Office LLC

Key Points

• Callan Family Office LLC has acquired 2,881 shares of Astera Labs, Inc. valued at approximately $260,000 in the second quarter.
• A multiple of hedge funds have increased their stakes in Astera Labs, with US Bancorp DE growing holdings by 222.8% during the same period.
• Astera Labs reported a revenue increase of 149.5% year-over-year, reaching $191.93 million this quarter, and beat earnings per share estimates.

Callan Family Office LLC bought a new position in shares of Astera Labs, Inc. (NASDAQ:ALAB - Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The fund bought 2,881 shares of the company's stock, valued at approximately $260,000.

Several other hedge funds have also recently bought and sold shares of the business. Blair William & Co. IL lifted its stake in shares of Astera Labs by 50.4% during the second quarter. Blair William & Co. IL now owns 12,975 shares of the company's stock worth $1,173,000 after purchasing an additional 4,350 shares in the last quarter. US Bancorp DE grew its holdings in Astera Labs by 222.8% during the 2nd quarter. US Bancorp DE now owns 9,978 shares of the company's stock valued at $902,000 after purchasing an additional 6,887 shares in the last quarter. Rye Brook Capital LLC purchased a new stake in Astera Labs during the 2nd quarter worth $823,000. Maryland State Retirement & Pension System lifted its holdings in Astera Labs by 37.7% in the 2nd quarter. Maryland State Retirement & Pension System now owns 6,960 shares of the company's stock worth $629,000 after buying an additional 1,906 shares in the last quarter. Finally, Virtus Wealth Solutions LLC lifted its holdings in Astera Labs by 81.6% in the 2nd quarter. Virtus Wealth Solutions LLC now owns 81,165 shares of the company's stock worth $7,339,000 after buying an additional 36,465 shares in the last quarter. Hedge funds and other institutional investors own 60.47% of the company's stock.

Astera Labs Price Performance

Shares of ALAB stock opened at $163.55 on Friday. Astera Labs, Inc. has a 12-month low of $47.13 and a 12-month high of $262.90. The firm has a market capitalization of $27.19 billion, a price-to-earnings ratio of 292.05, a price-to-earnings-growth ratio of 4.02 and a beta of 1.43. The business has a 50 day simple moving average of $200.07 and a 200 day simple moving average of $127.18.

Astera Labs (NASDAQ:ALAB - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.33 by $0.11. Astera Labs had a net margin of 16.54% and a return on equity of 9.53%. The business had revenue of $191.93 million during the quarter, compared to analysts' expectations of $172.46 million. During the same period last year, the firm posted $0.13 earnings per share. The business's revenue was up 149.5% on a year-over-year basis. Astera Labs has set its Q3 2025 guidance at 0.380-0.390 EPS. On average, equities analysts anticipate that Astera Labs, Inc. will post 0.34 EPS for the current fiscal year.

Insider Transactions at Astera Labs

In related news, Director Stefan A. Dyckerhoff sold 25,000 shares of the company's stock in a transaction that occurred on Thursday, August 7th. The shares were sold at an average price of $173.42, for a total value of $4,335,500.00. Following the completion of the sale, the director owned 99,154 shares in the company, valued at approximately $17,195,286.68. This represents a 20.14% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Jitendra Mohan sold 152,517 shares of the stock in a transaction dated Thursday, August 7th. The stock was sold at an average price of $170.33, for a total value of $25,978,220.61. Following the completion of the sale, the chief executive officer directly owned 450,001 shares of the company's stock, valued at approximately $76,648,670.33. This represents a 25.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,182,514 shares of company stock worth $202,298,671 in the last three months. Insiders own 12.50% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently commented on ALAB shares. Susquehanna increased their price target on Astera Labs from $80.00 to $125.00 and gave the company a "neutral" rating in a report on Thursday, August 7th. Weiss Ratings reiterated a "hold (c-)" rating on shares of Astera Labs in a research note on Wednesday, October 8th. Barclays reaffirmed an "overweight" rating and issued a $155.00 price target (up from $75.00) on shares of Astera Labs in a report on Thursday, August 7th. Zacks Research lowered shares of Astera Labs from a "strong-buy" rating to a "hold" rating in a report on Monday, October 6th. Finally, Morgan Stanley increased their price target on shares of Astera Labs from $155.00 to $200.00 and gave the stock an "overweight" rating in a research report on Friday, August 29th. Fifteen research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company's stock. According to data from MarketBeat.com, Astera Labs has a consensus rating of "Moderate Buy" and an average price target of $159.83.

Astera Labs Profile

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.

Want to see what other hedge funds are holding ALAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astera Labs, Inc. (NASDAQ:ALAB - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.